Pemberian Kombinasi 5FU-Leucovorin dengan Phaleria macrocarpa terhadap Proliferasi Sel dan Diameter Adenokarsinoma Kolon Tikus Sprague dawley

Authors

  • Luqman Alwi Diponegoro University
  • Selamat Budijitno Diponegoro University
  • Edwin Basyar Diponegoro University

DOI:

https://doi.org/10.21776/ub.jkb.2017.029.03.7

Keywords:

Adenokarsinoma kolon, P. macrocarpa, proliferasi sel

Abstract

Insidensi kanker kolon di seluruh dunia masih tinggi dan menjadi penyebab kematian terbanyak kategori penyakit tidak menular. Pembedahan tetap merupakan pilihan utama dengan modalitas lainnya berupa kemoterapi, radiasi dan imunoterapi seperti P. macrocarpa (Mahkota Dewa). Penelitian dilakukan dengan desain eksperimental laboratorik dengan desain post test only menggunakan tikus putih betina strain Sprague dawley dibagi menjadi 4 kelompok yaitu kelompok K (kontrol), P1 (kelompok kemoterapi), P2 (kelompok P. macrocarpa), dan P3 (Kelompok kombinasi). Tumor kolon diperoleh dengan induksi 1,2-DMH subkutan. Kemoterapi yang diberikan 5FU-Leucovorin sebanyak 6 siklus sesuai Rosswell Park Regiment. P. macrocarpa diberikan dengan dosis 0,495mg/hari (0,99mL/hari) per oral. Proliferasi sel dinilai dengan pengecatan IHC Ki-67 sedangkan diameter massa tumor diukur menggunakan caliper tumor. Proliferasi sel dan diameter massa tumor didapatkan rerata kelompok K, P1, P2, P3 berturut-turut 37,150±8,878, 28,567±12,531, 35,533±8,982, 22,567±3,445 dan 1,403±0,265, 1,135±0,154, 1,339±0,111, 1,074±0,164. Analisis statistik menunjukkan terdapat perbedaan bermakna pada proliferasi sel antara kelompok K vs P3 (p=0,011), P2 vs P3 (p=0,022) dan pada diameter massa tumor antara kelompok K vs P1 (p=0,020), K vs P3 (p=0,005), P2 vs P3 (0,021). Analisis korelasi proliferasi sel dengan diameter massa tumor didapatkan korelasi tidak bermakna (p=0,405). P. macrocarpa mempunyai potensi sebagai imunostimulator yang dapat meningkatkan efektivitas kemoterapi 5FU-Leucovorin dalam hal penurunan proliferasi sel dan penurunan diameter adenokarsinoma kolon tikus Sprague dawley.
Kata Kunci: Adenokarsinoma kolon, P. macrocarpa, proliferasi sel

 

Downloads

Download data is not yet available.

References

Department of Health and Human Services, Centers for Disease Control and Prevention. U.S. Cancer Statistics Working Group. (Online) Apr. 2011. http://www.cdc.gov/cancer/npcr/uscs/about.htm [accessed on 17 April 2013]

Committee on the Use of Complementary and Alternative Medicine by The American Public. Complementary and Alternative Medicine in the United States. Washington: The National Academic Press; 2005.

Gangga E, Asriani H, dan Novita L. Analisis Pendahuluan Metabolit Sekunder dari Kalus Mahkota Dewa (Phaleria Macrocarpa [Scheff.] Boerl.). Jurnal Ilmu Kefarmasian Indonesia. 2007; 5(1): 17-22.

Harmanto N. Mahkota Dewa Obat Pusaka Para Dewa: A Medicine the Legacy of the Gods. 7th edition. Jakarta: Agro Media Pustaka; 2007.

Lisdawati V. Mahkota Dewa: Toksisitas, Efek Antioksidan dan Efek Antikanker Berdasarkan Uji Penapisan Farmakologi. (Online) April 2012. http: //www.indonetwork.phalerindofarma/34716.htm [accessed on 18 April 2013].

Hendra R, Ahmad S, Oskoueian E, Sukari A, and Shukor MY. Antioxidant, Anti-Inflammatory and Cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit. BMC Complementary and Alternative Medicine. 2011; 11: 110-119.

Deguchi H, Fujii T, Nakagawa S, Koga T, and Shirouzu K. Analysis of Cell Growth Inhibitory Effect of Cathechin Through MAPK in Human Breast Cancer Cell Line T47D. International Journal Oncology. 2002; 21(6): 1301-1305.

Kusmardiyani S, Nawawi A, dan Rahmi K. Isolasi Benzofenon dari Daun Mahkota Dewa [Phaleria macrocarpa (Scheff.) Boerl.]. Acta Pharmaceutica Indonesia. 2005; 4: 150-152.

Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, and Scholzen T. Ki-67 Protein is Associated with Ribosomal RNA Transcription in Quiescent and Proliferating Cells. Journal of Cellular Physiology. 2006; 206(3): 624–635.

World Health Organization Regional Office for the Western Pacific. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicine. Manila: WHO Regional Office for the Western Pacific; 1993.

Boyiadzis MM, Lebowitz PF, Frame JN, Fojo T. Hematology-oncology Therapy. New York: McGraw-Hill; 2006.

Saltz and LB and Kemeny NE. Adjuvant Chemotherapy for Colorectal Cancer. The Oncologist. 1996; 1(1-2): 22-29.

Dani V, Goel A, Vaiphei K, Dhawa DK. Chemopreventive Potential of Zinc in Experimentally Induced Colon Carcinogenesis. Toxicollogy Letters. 2007; 171(1-2): 10-18.

Faried A, Kurnia D, Faried LS et al. Anticancer Effects of Gallic Acid Isolated from Indonesian Herbal Medicine Phaleria macrocarpa (Scheff.) Boerl on Human Cancer Cell Lines. International Journal of Oncology. 2007; 30(3): 605-613.

De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, and Kim SH. Structural Basis for Specifity and Potency of a Flavonoid Inhibitor of Human CDK2, a Cell Cycle Kinase. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(7): 2735–2740.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000; 92(3): 205-216.

Balta AZ, Ozdemir Y, Sucullu I, et al. Can Horizontal Diameter of Colorectal Tumor Help Predict Prognosis? Ulusal Cerrahi Dergisi. 2014; 30(3): 115-119.

Riwanto I, Budijitno S, Dharmana E, et al. Effect of Phaleria macrocarpa Supplementation on Apoptosis and Tumor Growth of C3H Mice with Breast Cancer Under Treatment with Adriamycin-Cyclophosphamide. International Surgery. 2011; 96(2): 164-170.

Budijitno S, Issakh B, Handojo D, Pudjonarko D, dan Riwanto I. Pengaruh Ekstrak Mahkota Dewa terhadap Skor Ekspresi Perforin CTL dan Sel NK serta Indeks Apoptosis pada Adenokarsinoma Mamma Mencit C3H. Jurnal Kedokteran Media Medika Indonesiana. 2007; 42(1).

Guzińska-Ustymowicz K, Stepień E, and Kemona A. MCM-2, Ki-67 and PCNA Protein Expressions in pT3G2. Colorectal Cancer Indicated Lymph Node Involvement. Anticancer Research. 2008; 28(1B): 451-457.

Lu C, Liu L, Wu X, and Xu W. CD133 and Ki-67 Expression is Association with Gastrointestinal Stromal Tumor Prognosis. Oncollogy Letters. 2013; 6(5): 1289-1294.

Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of Bcl-2 Oncoprotein Immunohistochemical Expression with Proliferation Index and Histopathologic Parameters in Colorectal Neoplasia. Pathology Oncology Research. 1999; 5(4): 273-279.

Ingolf J, Russalina M, Simona M, et al. Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy? BioMed Research International. 2014; 2014: 7.

Kalogeraki A, Tzardi M, Zoras O, et al. Apoptosis and Cell Proliferation Correlated with Tumor Grade in Patients with Lung Adenocarcinoma. In Vivo. 2010; 24(5): 667-670.

Lee LH, Yang H, and Bigras G. Current Breast Cancer Proliferative Markers Correlate Variably Based on Decoupled Duration Cell Cycle Phases. Scientific Reports. 2014; 4: 8.

Komprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of Tumor Size as a Prognostic Variable in Colorectal Cancer: A Critical Reappraisal. American Journal of Clinical Oncology. 2011; 34(1): 43-49.

Todosi A, Hutanu I, Gavrilescu MM, Moscalu M, Ferariu D, and Scripcariu V. Assessment of Tumor Parameters as Factors of Aggressiveness in Colon Cancer. Journal of Surgery [Jurnalul de Chirurgie]. 2015; 10(4): 291-295.

Downloads

Published

2016-12-29

Issue

Vol 29, No. 3 (2017)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).